This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Herbert Y. Meltzer, MD; Victor S. Fang, PhD

Arch Gen Psychiatry. 1976;33(3):279-286.

Abstract
• Serum prolactin levels were studied before and during longterm administration of phenothiazines on a twice daily schedule to 27 newly admitted schizophrenic patients. An increase in serum prolactin is believed to be a reflection of inhibition of dopamine receptors in the hypothalamopituitary axis. By 72 hours after the initiation of treatment, all 27 patients had persistently elevated serum prolactin levels averaging 3.2-fold and 3.8-fold in men and women, respectively. There was a lag between clinical response and dopamine blockade, as indicated by serum prolactin levels in most patients. Serum prolactin levels remained elevated during the one- to three-month period subjects were studied, suggesting there was no tolerance to this effect of phenothiazines. Serum prolactin levels tended to be higher with thioridazine than on equivalent doses of chlorpromazine or trifluoperazine hydrochloride. There was some evidence that the magnitude of the serum prolactin elevation correlated with clinical response. After cessation of phenothiazines, serum prolactin levels rapidly reverted to normal within 48 to 96 hours.

Author Affiliations
From the departments of psychiatry (Dr Meltzer) and medicine (Dr Fang), University of Chicago Pritzker School of Medicine, and the Illinois State Psychiatric Institute (Dr Meltzer).

Footnotes
Accepted for publication Nov 10, 1975.

Reprint requests to Department of Psychiatry, University of Chicago Pritzker School of Medicine, 950 E 59th St, Chicago, IL 60637 (Dr Meltzer).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases
Akkaya et al.
J Psychopharmacol 2009;23:723-726.
ABSTRACT  

Clinical questions and uncertainty -- prolactin measurement in patients with schizophrenia and bipolar disorder
Walters and Jones
J Psychopharmacol 2008;22:82-89.
ABSTRACT  

Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma
Dunkley and Reveley
J Psychopharmacol 2005;19:97-101.
ABSTRACT  

Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences: Selective literature review
WIECK and HADDAD
Br. J. Psychiatry 2003;182:199-204.
ABSTRACT | FULL TEXT  

Toxicity and Carcinogenicity Studies of Chlorpromazine Hydrochloride and p-Cresidine in the p53 Heterozygous Mouse Model
Petruska et al.
Toxicol Pathol 2002;30:696-704.
ABSTRACT  

Hyperprolactinaemia caused by antipsychotic drugs
Wieck and Haddad
BMJ 2002;324:250-252.
FULL TEXT  

Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports
Haddad et al.
J Psychopharmacol 2001;15:293-295.
ABSTRACT  

Low dose typical antipsychotics - a brief evaluation
Taylor
Psychiatr. Bull. 2000;24:465-468.
FULL TEXT  

Effect of Risperidone on Prolactinoma Growth in a Psychotic Woman
Pal and Sarino
Psychosom. Med. 2000;62:736-738.
ABSTRACT | FULL TEXT  

Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and Clozapine: Relation to Extrapyramidal Side Effects
Farde et al.
Arch Gen Psychiatry 1992;49:538-544.
ABSTRACT  

Haloperidol: Plasma Levels and Prolactin Response as Predictors of Clinical Improvement in Schizophrenia: Chemical v Radioreceptor Plasma Level Assays
Smith et al.
Arch Gen Psychiatry 1984;41:1044-1049.
ABSTRACT  

Growth Hormone and Prolactin Response to Apomorphine in Schizophrenia and the Major Affective Disorders: Relation to Duration of Illness and Depressive Symptoms
Meltzer et al.
Arch Gen Psychiatry 1984;41:512-519.
ABSTRACT  

The Effect of Buspirone on Prolactin and Growth Hormone Secretion in Man
Meltzer et al.
Arch Gen Psychiatry 1983;40:1099-1102.
ABSTRACT  

High Doses of Haloperidol in Schizophrenia: A Clinical, Biochemical, and Pharmacokinetic Study
Zarifian et al.
Arch Gen Psychiatry 1982;39:212-215.
ABSTRACT  

Differential Effects of Neuroleptic Agents on the Pituitary-Gonadaln Axis in Men
Brown et al.
Arch Gen Psychiatry 1981;38:1270-1272.
ABSTRACT  

Motility, Parkinsonism, and Prolactin With Thiothixene and Thioridazine
Crowley and Hydinger-Macdonald
Arch Gen Psychiatry 1981;38:668-675.
ABSTRACT  

Serum Haloperidol Determinations in Psychiatric Patients: Comparison of Methods and Correlation With Serum Prolactin Level
Rubin et al.
Arch Gen Psychiatry 1980;37:1069-1074.
ABSTRACT  

TRH (Protirelin) in Depressed Alcoholic Men: Behavioral Changes and Endocrine Responses
Loosen et al.
Arch Gen Psychiatry 1979;36:540-547.
ABSTRACT  

Neuroleptic-induced Prolactin Level Elevation and Breast Cancer: An Emerging Clinical Issue
Schyve et al.
Arch Gen Psychiatry 1978;35:1291-1301.
ABSTRACT  

Relation of Plasma Prolactin to Clinical Response in Schizophrenic Patients
Gruen et al.
Arch Gen Psychiatry 1978;35:1222-1227.
ABSTRACT  

Prolactin Responses to Neuroleptics in Normal and Schizophrenic Subjects
Gruen et al.
Arch Gen Psychiatry 1978;35:108-116.
ABSTRACT  

Antipsychotic Agents and Serum Prolactin Levels
Gold
JAMA 1976;236:2175-2175.
ABSTRACT